BioSpace News Archive

Novavax, Inc. today announced changes to its executive leadership team designed to enhance focus on its strategic priorities and continue the evolution of the Company’s scale and structure announced last week.

Virpax ® Pharmaceuticals, Inc. today announced that it received a notice (the “Notice”) from the Listing Qualifications Staff of the Nasdaq Stock Market (“Nasdaq”) on November 16, 2023 stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1).

Parexel today announced today announced it has been named “Best Contract Research Organization” in the Full-Service Provider category at the 19th Annual Scrip Awards.

Benitec Biopharma Inc. today announced that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec, will participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference on Thursday, November 30th, 2023 at 10:00 am ET.

Avistone Biotechnology Co. Ltd. (“Avistone” or “the Company”) announced that they received conditional approval from the National Medical Products Administration (NMPA) to commercialize Vebreltinib (also referred to as PLB1001, APL-101, Bozitinib, CBT-101) to treat patients with MET exon 14 skipping non-small cell lung cancer (NSCLC) in China.

Immunexpress, Pty Ltd. today announced a poster presentation validating the utility of SeptiCyte® RAPID in patients who are immunocompromised or are receiving immunosuppressive therapy at the Association for Molecular Pathology (AMP) 2023 Annual Meeting.

Varex Imaging Corporation (Nasdaq: VREX) announced today that management is scheduled to participate in two upcoming investor conferences.

Altamira Therapeutics Ltd. today announced that it has entered into a binding agreement for the sale of a 51% stake in its subsidiary Altamira Medica AG (“Medica”) to a Swiss private equity investor as part of its strategic repositioning around its RNA delivery technology.

Genome Insight will announce new-real-world evidence from Hong Kong on the application of Target Enhanced Whole Genome Sequencing (TE-WGS) at the 2023 AACR-KCA joint conference on Precision Medicine in Cancer in Seoul, Korea.

BioMimetix JV, LLC, a clinical-stage biotechnology company developing metalloporphyrins, a novel drug class for the treatment of cancer patients, today announced the presentation of encouraging data from its Phase 2 study of lead candidate, BMX-001, for the treatment of high-grade glioma (HGG) at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting.